Ignite Creation Date:
2024-05-06 @ 7:30 PM
Last Modification Date:
2024-10-26 @ 3:08 PM
Study NCT ID:
NCT06036797
Status:
RECRUITING
Last Update Posted:
2023-10-26
First Post:
2023-09-07
Brief Title:
Efficacy and Safety of Hydromorphone-ropivacaine Versus Sufentanil-ropivacaine for Epidural Labor Analgesia
Sponsor:
Maternal and Child Health Hospital of Hubei Province
Organization:
Maternal and Child Health Hospital of Hubei Province
Study Overview
Official Title:
Efficacy and Safety of Hydromorphone-ropivacaine Versus Sufentanil-ropivacaine for Epidural Labor Analgesia a Randomized Controlled Trial
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the effects of three different doses of hydromorphone combined with ropivacaine and sufentanil combined with ropivacaine in epidural labor analgesia through prospective clinical trials so as to explore whether hydromorphone combined with ropivacaine has advantages in epidural labor analgesia and find out the optimal dose of hydromorphone
Participants will be randomly allocated to four groups Group 1 Group 2 Group 3 and Group 4 For those in Group 1 they will be administered with 15 ugml hydromorphone and 008 ropivacaine for epidural labor analgesia For those in Group 2 they will be administered with175 ugml hydromorphone and 008 ropivacaine for epidural labor analgesia For those in Group 3 they will be administered with 20 ugml hydromorphone and 008 ropivacaine for epidural labor analgesia For those in Group 4 they will be administered with 04 ugml sufentanil and 008 ropivacaine for epidural labor analgesia
The goal of this clinical trial is to provide a new treatment option for pregnant women in epidural labor analgesia and to provide a basis for hydromorphone combined with ropivacaine in epidural labor analgesia
Participants will be randomly allocated to four groups Group 1 Group 2 Group 3 and Group 4 For those in Group 1 they will be administered with 15 ugml hydromorphone and 008 ropivacaine for epidural labor analgesia For those in Group 2 they will be administered with175 ugml hydromorphone and 008 ropivacaine for epidural labor analgesia For those in Group 3 they will be administered with 20 ugml hydromorphone and 008 ropivacaine for epidural labor analgesia For those in Group 4 they will be administered with 04 ugml sufentanil and 008 ropivacaine for epidural labor analgesia
The goal of this clinical trial is to provide a new treatment option for pregnant women in epidural labor analgesia and to provide a basis for hydromorphone combined with ropivacaine in epidural labor analgesia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None